National Translational Science Center for Molecular Medicine and Department of Cell Biology, Fourth Military Medical University, Xi'an, Shaanxi, China.
Department of Clinical Immunology, PLA Specialized Research Institute of Rheumatology and Immunology, Xijing Hospital, Fourth Military Medical University, No. 15 Changle West Road, Xi'an, 710032, Shanxi Province, People's Republic of China.
Clin Rheumatol. 2024 Nov;43(11):3323-3333. doi: 10.1007/s10067-024-07134-9. Epub 2024 Sep 18.
To describe the development and validation of a novel patient reported scale, which is a comprehensive assessment of the physical function and health specific for patients with axial spondyloarthritis (axSpA).
This is a multiphase, mixed methods study. Based on opinion collection and discussions of multidisciplinary consensus meetings and patients, an initial item pool covering all of the ranges of functioning was generated. The item optimization, model fit, response category functioning, differential item functioning, reliability, structure validity, and unidimensionality were tested by confirmatory factor analysis and Rasch measurement theory framework.
After the consensus meeting and the two rounds of surveys in patients with axSpA, the initial pool of 135 items was reduced to 25 items formed in five dimensions, which exhibited preferable item reliability, item fit, and person fit to the Rasch model. The Five-Dimensional Comprehensive Assessment Scale (5DCAS) had the best reliability and validity (Kaiser-Meyer-Olkin was 0.919, and the standardized Cronbach's α coefficient was 0.932). The final version of 5DCAS had good unidimensionality, and the Person Separation Index ranged from 0.77 to 0.85. 5DCAS significantly correlated with ASAS-HI, SF-36, BASFI, and disease activity with p values of < 0.001.
5DCAS is a novel patient-reported outcome specific to axSpA, and it forms five dimensions providing a linear sum score of 25 items. 5DCAS comprehensively and significantly represents the physical function and health status of patients with axSpA, although its performance needs further validation in future clinical practices. Key Points • The primary goal in the management of axial spondyloarthritis is to maximize health-related quality of life. Except for the current instruments of ASAS-HI, BASFI, or SF-36, the heterogeneous clinical symptoms and rapid updated treat-to-target concept require a new instrument which can comprehensive and significant evaluate the changes of physical function and health-related quality of life due to disease. • 5DCAS is a novel patient-reported outcome specific to axSpA, and it forms five dimensions providing a linear sum score of 25 items, which contained aspect of pain involvement, spine mobility, global body performance and activity, social participation and environment, and mental health. All of the items were set to a 4-point semantic rating scale measuring severity, frequency, or interference from score 0 to 3. Total 5DCAS score ranges from 0 to 75; higher scores represented greater symptom burden and worse physical function. • 5DCAS is a comprehensive, multidisciplinary, and convenient disease outcome measurement specific for axSpA. It provides a new evaluation instrument in clinical trial and treat-to-target clinical remission for patients and physicians, and also provides a sensitive and accurate assessment standard for optimized health benefits.
描述一种新的患者报告量表的开发和验证,该量表专门针对中轴型脊柱关节炎(axSpA)患者的身体功能和健康状况进行全面评估。
这是一个多阶段、混合方法研究。基于多学科共识会议和患者的意见收集和讨论,生成了一个初步的项目池,涵盖了所有功能范围。通过验证性因子分析和 Rasch 测量理论框架测试项目优化、模型拟合、反应类别功能、差异项目功能、可靠性、结构有效性和维度不变性。
在共识会议和 axSpA 患者的两轮调查之后,最初的 135 个项目池减少到由五个维度组成的 25 个项目,这些项目在 Rasch 模型中表现出较好的项目可靠性、项目拟合和个体拟合。五维度综合评估量表(5DCAS)具有最佳的可靠性和有效性(Kaiser-Meyer-Olkin 为 0.919,标准化 Cronbach's α 系数为 0.932)。最终版本的 5DCAS 具有良好的单维性,个体分离指数范围为 0.77 至 0.85。5DCAS 与 ASAS-HI、SF-36、BASFI 和疾病活动度显著相关(p 值均<0.001)。
5DCAS 是一种针对 axSpA 的新型患者报告结局评估工具,它由五个维度组成,提供 25 个项目的线性总和评分。5DCAS 全面且显著地代表了 axSpA 患者的身体功能和健康状况,尽管其性能在未来的临床实践中需要进一步验证。
中轴型脊柱关节炎管理的主要目标是最大限度地提高与健康相关的生活质量。除了目前的 ASAS-HI、BASFI 或 SF-36 等工具外,由于疾病的异质性临床症状和快速更新的达标治疗理念,需要一种新的工具,能够全面而显著地评估身体功能和健康相关生活质量的变化。
5DCAS 是一种针对 axSpA 的新型患者报告结局评估工具,它由五个维度组成,提供 25 个项目的线性总和评分,涵盖疼痛、脊柱活动度、整体身体表现和活动、社会参与和环境以及心理健康等方面。所有项目均设置为 4 分语义评分量表,测量严重程度、频率或干扰程度,评分范围为 0 至 3。总 5DCAS 评分范围为 0 至 75;分数越高,表明症状负担和身体功能越差。
5DCAS 是一种专门针对 axSpA 的全面、多学科、便捷的疾病结局测量工具。它为患者和医生提供了一种新的临床试验和达标治疗缓解评估工具,也为优化健康效益提供了一种敏感和准确的评估标准。